Skip to main content
. 2021 Jun 15;12:678570. doi: 10.3389/fimmu.2021.678570

Figure 3.

Figure 3

Detailed characterization of SARS-CoV-2 antibodies. (A) Evaluating the cross reactivity of 155 SARS-CoV-2 antibodies to SARS-CoV-1 RBD and MERS CoV S1. CR3022, a previously published binding SARS-CoV-1 and SARS-CoV-2 cross reactive antibody was used as control. (B) Authentic SARS-CoV-2 neutralizing activity of a panel of 21 SARS-CoV-2 antibodies and control antibodies. (C) Comparing authentic SARS-CoV-2 neutralizing activity of 4 antibodies, in Fab and IgG format. Error bars indicate standard deviation. (D) Epitope binning of SARS-CoV-2 antibody panel using Octet BioLayer interferometry. The bins are labeled A to G. ​Antibodies in bold text denote capture molecules that exhibited unidirectionality.